Price · as of 2024-12-31
$0.77
Market cap 7.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.24 | +2,933.94% |
| Intrinsic Value(DCF) | $0.59 | -22.98% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $101.00 | ||||
| 2013 | $197.10 | $104.66 | $5.53 | $4.07 | $0.00 |
| 2014 | $89.30 | $55.17 | $3.74 | $1.73 | $4.94 |
| 2015 | $69.00 | $49.36 | $3.13 | $0.70 | $9.69 |
| 2016 | $51.30 | $47.19 | $2.38 | $0.00 | $24.08 |
| 2017 | $39.00 | $39.91 | $1.67 | $0.00 | $30.91 |
| 2018 | $20.70 | $35.46 | $0.99 | $0.00 | $30.76 |
| 2019 | $12.00 | $31.27 | $0.91 | $0.00 | $32.49 |
| 2020 | $55.90 | $48.63 | $0.44 | $0.00 | $0.00 |
| 2021 | $12.30 | $27.70 | $0.45 | $0.00 | $1.36 |
| 2022 | $6.70 | $17.66 | $0.00 | $0.00 | $0.00 |
| 2023 | $9.30 | $34.13 | $0.09 | $0.00 | $0.00 |
| 2024 | $1.48 | $23.24 | $0.43 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Evogene Ltd.'s (EVGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.24
- Current price
- $0.77
- AI upside
- +2,933.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.59
-22.98% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EVGN | Evogene Ltd. | $0.77 | 7.65M | +2,934% | -23% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLRB | Cellectar Biosciences, In… | $3.25 | 10.36M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| IMNN | Imunon, Inc. | $3.25 | 8.19M | — | — | — | — | -0.56 | 2.47 | — | -0.32 | — | 2.47 | 0.00% | — | — | -211.21% | 3263.61% | -117.72% | 0.27 | — | 1.67 | 1.23 | 0.26 | -2500.00% | — | -303.00% | -180.33% | -3.94 | 3221.31% | 0.00% | 0.00% | 4.96% | -0.30 | -0.30 | — | -63.56 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| SNSE | Sensei Biotherapeutics, I… | $30.50 | 38.48M | — | — | — | — | -7.50 | 5.89 | — | -6.39 | — | 5.89 | 0.00% | — | — | -58.40% | -1014.51% | -50.37% | 0.10 | -351.81 | 7.70 | 7.59 | 0.21 | -164.00% | — | -2294.00% | -10.98% | -4.53 | -795.13% | 0.00% | 0.00% | 0.00% | -5.96 | -7.60 | — | 10.02 |
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
- CEO
- Ofer Haviv
- Employees
- 117
- Beta
- 1.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.59 ÷ $0.77) − 1 = -22.98% (DCF, example).